NEVRO CORP. (NYSE:NVRO) Files An 8-K Results of Operations and Financial Condition

On July 16, 2018, Nevro Corp. (“Nevro” or the “Company”) issued a press release announcing its preliminary unaudited revenue for the second quarter ended June 30, 2018. A copy of the press release is furnished as Exhibit 99.1 to this report.

The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission (the “SEC”) made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

NEVRO CORP ExhibitEX-99.1 2 nvro-ex991_56.htm EX-99.1 nvro-ex991_56.htm Exhibit 99.1   Nevro Announces Preliminary Unaudited Second Quarter 2018 Revenue and Updates Full Year 2018 Revenue Guidance Company to Host Conference Call Today,…To view the full exhibit click here
About NEVRO CORP. (NYSE:NVRO)
Nevro Corp. is a medical device company. The Company has developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is a spinal cord stimulation (SCS) system that delivers its HF10 therapy. HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy offers back pain relief in addition to leg pain relief. HF10 therapy also provides pain relief without paresthesia. HF10 therapy offers benefits to patients, physicians and hospitals. The Company’s Senza is designed to create electrical impulses from 2 hertz to 10 kilohertz (kHz), including its HF10 therapy. HF10 therapy delivers waveforms at 10 kHz pulse rate with a statistically driven and clinically verified programming algorithm. Senza consists of leads, a trial stimulator, an implantable pulse generator (IPG), surgical tools, a clinician laptop programmer, a patient remote control and a mobile charger.